Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 309

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 309
---
 | ​ | ​                              | $ |  31,614 | ​ | ​ | ​ | ​    | $ |  22,919 | ​ | ​ |
| Non-cash investing and financing activities                                 | ​ | ​ | ​                              | ​ |       ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ |
| Deferred offering costs included in accounts payable and accrued expenses   | ​ | ​ | ​                              | $ |   1,508 | ​ | ​ | ​ | ​    | $ |       — | ​ | ​ |

The accompanying notes are an integral part of these financial statements. F-7

TABLE OF CONTENTS

#### Tvardi Therapeutics, Inc.

### Notes to Financial Statements

### 1.   Nature of the Business and Basis of Presentation
Tvardi Therapeutics, Inc., Tvardi or the Company, incorporated on December 20, 2017, is a Delaware Corporation headquartered in Houston, Texas. The Company is a clinical-stage, biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Based upon its founder’s seminal work and deep understanding of the transcription factor, STAT3, the Company has designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, the Company is developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing. The Company’s lead product candidate, TTI-101, is currently in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis, IPF and hepatocellular carcinoma, HCC.

#### Risks and Uncertainties
The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful development of TTI-101 and TTI-109, the development of new technological innovations by competitors, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations and commercial success of TTI-101 and TTI-109. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or